Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Study uncovers gene that hides tumor cells from immunotherapy

A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients.

19 Jul 2019

Study: Megakaryocytes play an important role in cell migration

Hematopoiesis is the process of forming blood cells, which occurs predominantly in the bone marrow. The bone marrow produces all types of blood cells: red blood cells, platelets, and white blood cells.

18 Jul 2019

Single-cell encapsulation technology can protect transplanted MSCs from immune attack

Bone marrow transplants of hematopoietic stem cells have become standard treatment for a host of conditions including cancers of the blood and lymphatic systems, sickle cell anemia, inherited metabolic disorders, and radiation damage.

16 Jul 2019

Special blood test may predict relapse risk for breast cancer patients

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.

9 Jul 2019

Engineered stem cells offer new treatment for metastatic bone cancer

Engineered stem cells could help treat metastatic cancers in bone without killing normal surrounding bone.

9 Jul 2019

Mice cured of HIV in an experiment sparks new hope

HIV is a viral infection that leads to AIDS and is fatal in almost all cases. For decades now, researchers have been trying to find a complete cure for this infection that affects 37 million people across the globe.

4 Jul 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Multiple Sclerosis patients may have greater risk of developing cancer

New results of a 65-year follow-up study of nearly 7,000 Norwegian patients with Multiple Sclerosis suggest that patients may have a greater overall risk of developing cancer than the general population, with an especially high risk of cancer in respiratory organs, urinary organs and the central nervous system.

1 Jul 2019

Study: One-fifth of hematological cancer patients suffer blood clots or bleeding

New Danish research may help direct focus towards the serious complications that on average every fifth hematological cancer patient suffers.

27 Jun 2019

Scientists use advanced imaging to track brain tumor 'turncoats'

Glioblastomas, the deadliest type of brain tumor in adults, attract "turncoats." These are macrophages, a type of immune cell, which promote tumor progression and mask tumors from the immune system's scrutiny.

26 Jun 2019

Non-classical monocytes directly involved in regulation of immune response

Non-classical monocytes were long thought to play a purely surveillance role in the immune system. With the aid of a novel marker, Ludwig-Maximilians-Universitaet in Munich researchers have now shown that they are directly involved in the regulation of immune response

24 Jun 2019

Researchers highlight need for ethnic and ancestral diversity in large-scale genomic studies

A new multicenter analysis led by researchers at the Fred Hutchinson Cancer Research Center, the Icahn School of Medicine at Mount Sinai and other institutions found the inclusion of diverse, multiethnic populations in large-scale genomic studies is critical for reducing health disparities and accurately representing genetics-related disease risks in all populations.

20 Jun 2019

Investigational drug for treatment of sickle cell disease shows early promise in clinical trials

An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers at the European Hematology Association Congress in Amsterdam this week.

20 Jun 2019

Research findings lead to new clinical trial for people with myelofibrosis

Researchers at Huntsman Cancer Institute at the University of Utah (U of U) discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells.

20 Jun 2019

Henry Ford Cancer Institute treats its first patient with CAR T-cell therapy

Henry Ford Cancer Institute has treated its first patient with CAR T-cell therapy, an approach that uses engineered cells from a patient's immune system to destroy cancer.

18 Jun 2019

More screening and new treatments needed for sickle cell disease

The promise of new treatments for sickle cell disease, a group of inherited red blood cell disorders, has never been so great, but it will only be realized if there is constant investment in health policies such as programs for screening newborns, especially in sub-Saharan Africa, where most cases occur.

13 Jun 2019

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.

11 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Nanotechnology treatment reverses multiple sclerosis symptoms in mice

A nanotechnology treatment derived from bone marrow stem cells has reversed multiple sclerosis symptoms in mice and could eventually be used to help humans, according to a new study led by University of California, Irvine researchers.

6 Jun 2019